Announcements
- EQS-News: Sartorius to advance drug discovery and manufacturing with AI in collaboration with NVIDIA
- EQS-News: Sartorius collaborates with Sanofi to commercialize end-to-end platform for downstream process intensification
- EQS-AFR: Sartorius AG: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements
- EQS-News: Sartorius: First quarter results in line with expectations; recurring business with significant order growth; demand from China remains weak; outlook for full year confirmed
- EQS-DD: Sartorius AG: Dr. Florian Funck, Transfer of 1207 preference shares as a share-based remuneration component in fulfillment of a grant made before the start of the Management Board mandate.
- EQS-DD: Sartorius AG: Dr. Florian Funck, Transfer of 1500 ordinary shares as a share-based remuneration component in fulfillment of a grant made before the start of the Management Board mandate.
- EQS-News: Resolutions of the Annual General Meeting of Sartorius AG
More ▼
Key statistics
As of last trade, Sartorius AG (SRT3:BRN) traded at 271.10, 29.28% above the 52 week low of 209.70 set on Oct 30, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 264.21 |
---|---|
High | 271.10 |
Low | 264.21 |
Bid | 272.72 |
Offer | 273.56 |
Previous close | 271.10 |
Average volume | 20.00 |
---|---|
Shares outstanding | 74.88m |
Free float | 32.69m |
P/E (TTM) | 96.36 |
Market cap | 17.75bn EUR |
EPS (TTM) | 2.18 EUR |
Annual div (ADY) | 0.7236 CHF |
---|---|
Annual div yield (ADY) | 0.27% |
Div ex-date | Apr 02 2024 |
Div pay-date | Apr 04 2024 |
Data delayed at least 15 minutes, as of May 16 2024.
More ▼